

HEMOGLOBIN A1C-DIRECT (HbA1C-DIR)

| | |
|---|---------------------------------|
| COD 22047 2 x 60 mL + 2 x 12 mL | COD 22147 1 x 60 mL + 1 x 12 mL |
| Only for <i>in vitro</i> use in the clinical laboratory | |



HEMOGLOBIN A1C-DIRECT (HbA1C-DIR)
DIRECT

INTENDED USE

Reagents for the measurement of hemoglobin A1C (HbA1C) concentration in human blood. The obtained values are useful as an aid in the diagnosis and monitoring of diabetes mellitus.

This reagent is for use in the BioSystems BA analyzers or in other analyzer with similar performance characteristics.

CLINICAL SIGNIFICANCE

HbA1C is the product of the irreversible condensation of glucose with the N-terminal residue of the β-chain of hemoglobin A.

The HbA1C concentration in blood is directly proportional to the mean concentration of glucose prevailing in the previous 6-8 weeks, equivalent to the lifetime of the erythrocytes¹, and the estimated average glucose (eAG) during this period can be calculated with the formulas below².

$$\begin{aligned} \text{eAG (mg/dL)} &= 28.7 \times \text{HbA1C-NGSP-DCCT (\%)} - 46.7 \\ \text{eAG (mmol/L)} &= 1.59 \times \text{HbA1C-NGSP-DCCT (\%)} - 2.59 \\ \text{eAG (mg/dL)} &= 2.64 \times \text{HbA1C-IFCC (mmol/mol)} + 15.0 \\ \text{eAG (mmol/L)} &= 0.146 \times \text{HbA1C-IFCC (mmol/mol)} + 0.843 \end{aligned}$$

HbA1C levels are a valuable adjunct to glucose determinations in the assessment and follow up of individuals with diabetes mellitus, providing much more reliable information for glycaemia monitoring than do determinations of glucose. Numerous studies have shown that diabetes related complications may be reduced by the long term monitoring and tight control of blood glucose levels. The HbA1C concentration may also be a useful tool in the diagnosis of diabetes³.

Clinical diagnosis should not be made on the findings of a single test result, but should integrate both clinical and laboratory data.

PRINCIPLE OF THE METHOD

After preparing the hemolysate, the Hemoglobin A1C (HbA1C) concentration is quantified by a latex turbidimetric assay. The different hemoglobins present in the hemolysate are unspecifically adsorbed on the latex particles surface in a ratio equivalent to their concentration in the sample. The addition of an anti-human HbA1C antibody causes agglutination that is proportional to the concentration of hemoglobin A1C and can be measured by turbidimetry.

CONTENTS

| | COD 22047 | COD 22147 |
|------------|-----------|-----------|
| A. Reagent | 2 x 60 mL | 1 x 60 mL |
| B. Reagent | 2 x 12 mL | 1 x 12 mL |

COMPOSITION

- A. Reagent. Suspension of latex particles, sodium azide 0.95 g/L, pH 8.0.
- B. Reagent. Anti-human HbA1C antibody, stabilizers, pH 6.0.

STORAGE AND STABILITY

Store at 2-8 °C.

Components are stable once opened until the expiry date marked in the label if they are stored well closed and care is taken to prevent contamination during their use.

On board stability: Reagents open and kept in the refrigerated compartment of the analyzer are stable 30 days.

Indications of deterioration: Absorbance of the blank over the limit indicated in "Test Parameters".

ADDITIONAL MATERIALS REQUIRED (NOT PROVIDED)

S. HbA1C Direct Standards (cod. 31048), 4 levels for 0.5 mL. Human blood. HbA1C concentration is given on the label.

Human blood used in the preparation of the standard has been tested and found to be negative for the presence of antibodies anti-HIV and anti-HCV, as well as for HBs antigen. However, the standard should be handled cautiously as potentially infectious.

Reconstitute with 0.5 mL of distilled water. Stable for 30 days at 2-8°C. For longer periods, keep frozen. Avoid repeated freeze-thaw cycles.

REAGENT PREPARATION

Reagents are provided ready to use.

SAMPLES

Venous blood collected by standard procedures and with EDTA as anticoagulant.

HbA1C in blood is stable 7 days at 2-8°C.

PROCEDURE

Hemolysate preparation

The calibrators should be treated as patient samples.

- Pipette into a test tube:

| | |
|-----------------|--------|
| Blood | 50 µL |
| Distilled water | 5.0 mL |

- Mix gently. Avoid the formation of foam. Incubate at room temperature for 5 minutes.

The hemolysate is stable 72 hours at 2-8°C.

Test according to Test Parameters.

CALCULATION

The HbA1C values obtained are traceable to IFCC Reference Method.

The traceable values to Reference Method as described by the US National Glycohemoglobin Standardization Program (NGSP) are calculated using the following general formula⁴.

$$\% \text{HbA1C-NGSP-DCCT (\%)} = 0.0915 \times \text{HbA1C-IFCC (mmol/mol)} + 2.15$$

CALIBRATION

A reagent blank should be done every day and a calibration at least every 30 days, after reagent lot change or as required by quality control procedures.

QUALITY CONTROL

It is recommended to use the Hemoglobin A1C Controls, Normal (cod. 18001) and Elevated (cod. 18002) to verify the accuracy of the measurement procedure.

Each laboratory should establish its own internal Quality Control scheme and procedures for corrective action if control results are not within the acceptable limits.

REFERENCE VALUES

The following cut-off points have been established and adopted by many countries for a reference population (Non diabetic) and for the evaluation of the degree blood glucose control in diabetic patients^{1,5}.

| IFCC mmol/mol | NGSP-DCCT (%) | Reference values/Degree of control |
|---------------|---------------|------------------------------------|
| 20 - 38 | 4.0 - 5.6 | Non Diabetic |
| 39 - 47 | 5.7 - 6.4 | Pre-diabetic |
| > 48 | > 6.5 | Diabetic |
| < 53 | < 7.0 | Treatment Goal |

This range is given for orientation only; each laboratory should establish its own reference range.

METROLOGICAL CHARACTERISTICS

The metrological characteristics described below have been obtained using a BA400 analyzer and following the guidelines of the Clinical & Laboratory Standards Institute (CLSI).

- Detection limit: 1.9 mmol/mol
- Measurement interval: (approximate value dependent on the highest standard concentration): 2 - 140 mmol/mol.
- Precision:

| Mean concentration | Repeatability (CV) | Within-laboratory (CV) |
|--------------------|--------------------|------------------------|
| 34 mmol/mol | 3.3 % | 5.3 % |
| 70 mmol/mol | 1.5 % | 2.2 % |

- Trueness: Results obtained with this reagent did not show systematic differences when compared with reference reagents. Details of the comparison experiments are available on request.

LIMITATIONS OF THE PROCEDURE

- Interferences: Bilirubin (up to 10 mg/dL) and Lipemia (triglycerides up to 400 mg/dL) do not interfere. Other drugs and substances may interfere⁶.

In the immunoassay methods, the presence of acetylated-Hb, carbamylated-Hb, labile HbA1C HbE and HbD do not affect the results^{7,8}. Other hemoglobin variants like HbS, HbF or HbC can interfere⁷.

In hemolytic anemia, iron deficiency anemia and transfusion, the average age of erythrocytes is altered. Caution should be used when interpreting the HbA1C results from patients with these conditions.

NOTES

- To avoid possible interferences by other assays performing HbA1C determinations in different runs of the other test is recommended.

BIBLIOGRAPHY

- Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, 6th ed. Rifai N, Horvath AR, Wittwer CT. WB Saunders Co, 2018.
- Nathan DM, et al. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008; 31: 1473-1478.
- Nathan DM, et al. International Expert Committee report on the role of the HbA1C assay in the diagnosis of diabetes. Diabetes care 2009; 32: 1327-1334.
- Hoebel W et al. IFCC reference systems for measurement of hemoglobin A1C in human blood and the national standardization schemes in the United States, Japan and Sweden: a method-comparison study. Clin Chem 2004;50:166-174.
- American Diabetes Association Professional Practice Committee. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 Jan 1;45(Suppl 1):S17-S38. doi: 10.2337/dc22-S002. PMID: 34964875.
- Young DS. Effects of drugs on clinical laboratory tests, 5th ed. AACC Press, 2000.
- Bry L, Chen P, Sacks D. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem 2001;41:153-163.
- Little R.R., Rohlfing C; Hanson S, Connolly S, Weykamp C, D'Costa M, Luzzi V, Owen W, Roberts WL. Effects of Hemoglobin (Hb) E and HbD traits on measurements of Glycated Hb (HbA1C) by 23 methods. Clin Chem 2008, 54: 1277-1282.

TEST PARAMETERS (Notes 1 & 2)

These reagents may be used in several automatic analyzers. Specific instructions for application in many of them are available on request.

R1: Use Reagent A, R2: Use Reagent B.

| | BA200 | BA400 |
|------------------------------|-------------------------|-------------------------|
| GENERAL | | |
| Name | HbA1C-DIR | HbA1C-DIR |
| Short name | HbA1C-DIR | HbA1C-DIR |
| Sample type | WBL | WBL |
| Analysis mode | fixed-time bir. | fixed-time bir. |
| Unit | mmol/mol | mmol/mol |
| Decimals | 0 | 0 |
| Reaction type | increasing | increasing |
| PROCEDURE | | |
| Reading mode | monochromatic | monochromatic |
| Main filter | 670 | 670 |
| Reference filter | - | - |
| Sample | 3 | 3 |
| Vol. R1 | 190 | 190 |
| Vol. R2 | 40 | 40 |
| Reading 1 (cycle) | 19 | 37 |
| Reading 2 (cycle) | 34 | 70 |
| Predilution factor | - | - |
| CALIBRATION AND BLANK | | |
| Blank type | distilled water | distilled water |
| Calibration mode | experimental calibrator | experimental calibrator |
| Number of calibrators | 4 | 4 |
| Calibration curve | increasing polygonal | increasing polygonal |
| OPTIONS | | |
| Blank absorbance limit | 0.700 | 0.700 |
| Kinetic blank limit | - | - |
| Linearity limit | - | - |
| Substrate depletion | - | - |

